Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesClinical/Medical PolicyHealth New England PNS Prior Auth | OpenPayer
    Ask Trek AI about this page
    ModifiedHealth-New-EnglandPolicy UM570POL

    Peripherally Implanted Nerve Stimulation (PNS), Peripheral Subcutaneous Field Stimulation (PSFS), Percutaneous Electrical Nerve Field Stimulation (PENFS) - Medical Policy

    Customize your policy alerts

    Sign up for Health-New-England Policy UM570POL alerts

    Get alerted when Policy UM570POL changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization and medical-necessity coverage for PNS, PSFS/PNFS, and PENFS for Health-New-England Commercial, Medicare Advantage, and Medicaid BeHealthy members.

    Policy Summary
    PayerHealth-New-England
    PolicyPNS, PSFS/PNFS, and PENFS Medical Policy
    Policy CodePolicy UM570POL
    Change TypeModified
    Effective DateAugust 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit clinical evidence showing that the patient meets the applicable medical-necessity criteria.
    SourceLink
    POLICY UPDATE CHANGES

    InterQual Medicare procedure criteria were added for the Medicare line of business in April 2026.

    CPT 0702T was removed, CPT 64999 was updated, and CPT 64567 was added effective January 1, 2026.

    Criteria for the percutaneous electrical nerve field stimulation system were added in April 2025.

    The policy was moved to a new template in December 2023 and its line-of-business section was added in January 2024.

    Policy references were updated in February 2025.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    3 monthsMinimum chronic pain duration
    2Less-invasive modalities that must have failed
    ≥50%Successful permanent-stimulator trial pain reduction
    11–21PENFS age range
    9 monthsQualifying gastrointestinal symptom duration
    04/2026Medicare procedure criteria addition

    Medical Necessity and Coverage Criteria

    Initial PNS/PNFS Medical Necessity

    For Commercial and Medicaid members, PNS or PNFS using an FDA-approved peripheral nerve stimulator may be considered medically necessary when ALL of the following criteria are met. For Medicare members, HNE has adopted InterQual criteria for Electrical Nerve Stimulators, Peripheral Nerve Stimulator NCD, and Implanted Peripheral Nerve Stimulator; see NCD 160.7, Electrical Nerve Stimulators.

    ALL of the following

    • Chronic intractable pain for a minimum of 3 months that is refractory to at least two less-invasive treatment modalities, as appropriate to alleviate or cure the underlying condition causing the pain. Examples include, but are not limited to, physical therapy, braces, local injections, analgesics such as gabapentin or pregabalin, and acupuncture; or postsurgical and posttraumatic acute pain when FDA approved.
    • Appropriate documented patient education, including discussion and disclosure of treatment risks and benefits.
    • No active substance-abuse issues.
    • Formal psychological screening by a mental-health professional, with documentation of no psychological contraindications to using this treatment.
    • Objective evidence of pathology, such as findings on a nerve-conduction study or electromyogram.
    • No surgical contraindications, including infection or unacceptable medical risk.

    Permanent Implantable Stimulator

    A permanent implantable stimulator may be considered medically necessary only after the applicable initial requirements are met.

    ALL of the following

    • A successful stimulation trial produced a reduction in pain intensity of at least 50%.≥ 50% reduction in pain intensity

      A trial is not required for a temporary stimulator, such as Sprint.

    • ONE of the following pathways

      • Commercial/Medicaid pathway

        • The applicable initial PNS/PNFS criteria are met, including criteria 2 through 6: documented education and risk/benefit discussion; no active substance-abuse issues; formal psychological screening without psychological contraindications; objective evidence of pathology; and no surgical contraindications.
      • The applicable Medicare InterQual criteria are met for Electrical Nerve Stimulators, Peripheral Nerve Stimulator NCD, and Implanted Peripheral Nerve Stimulator.

    PENFS Medical Necessity

    The PENFS system (IB-STIM®) may be considered medically necessary in children and adolescents when ALL of the following criteria are met.

    ALL of the following

    • The patient is 11 through 21 years of age.11–21 years
    • The patient has a ROME IV-defined functional gastrointestinal disorder, including functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, or abdominal migraine.
    • Organic gastrointestinal disease has been ruled out, including inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, celiac disease, gallstones, and gastrointestinal cancers.
    • The problem has been present for at least 9 months.≥ 9 months

    Not Covered, Investigational, or Contraindicated Services

    The following services, indications, and circumstances are not covered, investigational, experimental, or contraindicated as specified below.

    Any of the following applies

    • PNS or PNFS is used to treat post-herpetic neuralgia, fibromyalgia, phantom limb pain, diffuse polyneuropathy, or angina pectoris; or is used for a non-FDA-approved indication. These uses are considered investigational.
    • PNS or PNFS criteria are not met. The service is considered not medically necessary.
    • Percutaneous electrical stimulation of a peripheral nerve using needles or needle electrodes is requested. This service is not covered.
    • An additional second or subsequent lead of a peripheral nerve stimulator is requested. This is considered experimental and investigational.
    • The requested PNS/PNFS service has a contraindication: BMI greater than 40, prior lumbar surgery, an implanted electronic device, or pregnancy.

    PNS or PNFS for post-herpetic neuralgia, fibromyalgia, phantom limb pain, diffuse polyneuropathy, or angina pectoris, and PNS or PNFS for non-FDA-approved indications, are considered investigational.

    Percutaneous electrical stimulation of a peripheral nerve using needles or needle electrodes is not covered.

    The use of a second or subsequent lead of a peripheral nerve stimulator is considered experimental and investigational.

    The PENFS system for indications other than the qualifying ROME IV-defined pediatric or adolescent functional gastrointestinal disorder criteria is considered experimental and investigational.

    Medical-necessity determinations do not constitute a representation or warranty that a service or supply is covered or will be paid by Health New England. Benefits programs may exclude services or supplies considered medically necessary. If this guideline conflicts with the member’s benefits program, the benefits program governs. Coverage may also be mandated by applicable state or federal law or by CMS for Medicare and Medicaid members.

    PNS or PNFS that does not meet the applicable medical-necessity criteria is considered not medically necessary.

    Coding and Threshold Reference

    CPT procedure codes with prior authorization requiredCPT
    64555Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve).
    64567Percutaneous electrical nerve field stimulation, cranial nerves, without implantation.
    64590Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver, requiring pocket creation and connection between electrode array and pulse generator or receiver.
    64596Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator, including imaging guidance, when performed; initial electrode array.
    64598Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator.
    64999Unlisted procedure, nervous system.
    Experimental/investigational useCPTExperimental
    64999Experimental/Investigational when used to describe percutaneous electrical stimulation of a peripheral nerve using needles or needle electrodes.
    Removed CPT codeCPT
    0702TCPT 0702T; removed effective 1/1/2026
    Updated CPT codeCPT
    64999CPT 64999; updated effective 1/1/2026 to include PENFS for MassHealth
    Added CPT codeCPT
    64567CPT 64567; added effective 1/1/2026
    Chronic intractable pain duration
    Minimum durationAt least 3 months of chronic intractable pain
    Treatment responsePain must be refractory to at least two less-invasive treatment modalities appropriate to the underlying condition
    ExceptionPostsurgical or posttraumatic acute pain may qualify when the indication is FDA approved
    Successful permanent-stimulator trial
    Required reductionAt least 50% reduction in pain intensity
    Timing

    Prior Authorization and Documentation Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for the listed stimulation procedures. Submit a PA request before performing the applicable service; CPT/HCPCS inclusion does not guarantee coverage or payment.

    • 64555 — Percutaneous implantation of neurostimulator electrode array; peripheral nerve
    • 64567 — Percutaneous electrical nerve field stimulation, cranial nerves, without implantation
    • 64590 — Insertion or replacement of peripheral, sacral, or gastric neurostimulator pulse generator or receiver
    • 64596 — Insertion or replacement of percutaneous electrode array, peripheral nerve, with integrated neurostimulator
    • 64598 — Revision or removal of neurostimulator electrode array, peripheral nerve, with integrated neurostimulator
    • 64999 — Unlisted nervous-system procedure; experimental/investigational when used for needle- or needle-electrode-based peripheral nerve stimulation
    Documentation Required

    Therapy Overview

    Peripheral nerve field stimulation (PNFS), also called peripheral subcutaneous field stimulation (PSFS), places electrode leads in subcutaneous tissue around a painful area to target a field of pain rather than a specific nerve. Percutaneous electrical nerve field stimulation (PENFS), including the IB-STIM system, is a nonsurgical stimulation therapy applied to branches of cranial and occipital nerves and used with other therapies for functional abdominal pain associated with qualifying gastrointestinal disorders.

    Stimulation Therapy Definitions

    Peripherally implanted nerve stimulation (PNS)
    Electrode placementElectrodes are surgically placed next to a selected peripheral nerve considered the source of chronic pain
    Therapeutic mechanismElectrical impulses are delivered to the affected nerve to disrupt pain-signal transmission and reduce pain
    System configurationA temporary system uses an external device; after a successful trial, a small generator may be implanted
    Peripheral nerve field stimulation (PNFS) / peripheral subcutaneous field stimulation (PSFS)
    Electrode placementElectrode leads are placed in subcutaneous tissue around the painful area
    Treatment targetElectrical current creates stimulation in the area, or field, of pain

    Prerequisite Treatment Failures

    Failure of at Least Two Less-Invasive Modalities

    For chronic intractable pain, both the duration requirement and treatment-failure requirement must be met.

    Less-invasive treatment failure

    • Qualifying pain duration or exception

      • Pain has been chronic for a minimum of 3 months.minimum 3 months
      • The indication is postsurgical or posttraumatic acute pain that is approved by the FDA.
    • The member is refractory to at least two less-invasive treatment modalities appropriate to alleviate or cure the underlying pain-generating condition.at least 2 failed modalities

    Diagnostic Evidence

    Documentation Required

    Provide objective diagnostic evidence

    For PNS or PNFS, submit objective diagnostic evidence of pathology. The policy gives nerve-conduction study or electromyogram as examples and does not mandate a specific imaging modality.

    • Include objective evidence supporting the underlying pathology.
    • A specific imaging modality is not required by this criterion.

    Noncovered Services and Indications

    The following PNS/PNFS uses are not covered or investigational: treatment of post-herpetic neuralgia, fibromyalgia, phantom limb pain, diffuse polyneuropathy, angina pectoris, and non-FDA-approved indications.

    Policy Summary
    PayerHealth-New-England
    PolicyPNS, PSFS/PNFS, and PENFS Medical Policy
    Policy CodePolicy UM570POL
    Change TypeModified
    Effective DateAugust 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization and submit clinical evidence showing that the patient meets the applicable medical-necessity criteria.
    SourceLink
    On This Page
    Medical Necessity and Coverage CriteriaCoding and Threshold ReferencePrior Authorization and Documentation RequirementsTherapy OverviewStimulation Therapy DefinitionsPrerequisite Treatment FailuresDiagnostic EvidenceNoncovered Services and Indications
    The patient has tried and failed medications in all three categories—acid suppression (H2 blockers or PPIs); antispasmodic or motility medications (hyoscyamine, dicyclomine, erythromycin, linaclotide, or prucalopride); and neuromodulators (amitriptyline, nortriptyline, gabapentin, Periactin, or aprepitant)—in addition to diet modification.
    The reduction must occur during a successful stimulation trial before permanent implantation
    Temporary stimulator exceptionA trial is not required for a temporary stimulator such as Sprint
    Qualifying PENFS symptom duration
    Minimum symptom durationQualifying gastrointestinal symptoms must have been present for at least 9 months
    Applicable therapyThe duration requirement applies to the PENFS system (IB-STIM)
    Additional requirementOrganic gastrointestinal disease must have been ruled out
    PENFS age
    Eligible age range11–21 years of age
    Eligible populationChildren and adolescents
    SystemPercutaneous electrical nerve field stimulation system (IB-STIM)
    BMI contraindication
    BMI thresholdBMI greater than 40
    Policy statusContraindication to PNS or PNFS
    Other listed contraindicationsPrior lumbar surgery, an implanted electronic device, or pregnancy
    Implanted-stimulator assessment trial
    Minimum trial durationAt least 1 month
    Documentation requiredThe physician must document whether the member is likely to derive significant therapeutic benefit from continued use of an implanted nerve stimulator
    When applicableFor implantation when pain is effectively controlled by percutaneous stimulation and implantation of electrodes is warranted

    Clinical Evidence Required for Prior Authorization

    Prior authorization requires clinical evidence supporting the requested treatment, testing, or surgical procedure and demonstrating that the applicable medical-necessity criteria are met. Evidence should address the diagnosis, duration and severity of symptoms, objective pathology, prior treatment response, FDA-approved indication where applicable, and all relevant eligibility and safety criteria.

    • Include pertinent clinical findings, diagnostic testing, treatment history, and relevant peer-reviewed or evidence-based support when needed for review.
    • For Medicare members, apply the adopted InterQual criteria and the Medicare Peripheral Nerve Stimulator NCD criteria, as applicable.
    Step Therapy

    Failure of Less-Invasive Treatment

    For PNS or PNFS, document chronic intractable pain for at least 3 months that is refractory to at least two appropriate less-invasive treatment modalities intended to alleviate or cure the underlying condition. Examples include physical therapy, braces, local injections, analgesics such as gabapentin or pregabalin, and acupuncture; FDA-approved post-surgical or post-traumatic acute pain is also addressed by the policy.

    • Identify each less-invasive modality attempted, including dates, duration, response, and reason it was inadequate, intolerable, or not appropriate.
    • The two-modality requirement applies to the chronic intractable pain pathway; do not rely on an undocumented treatment history.

    Unsupported block type: step_therapy

    Documentation Required

    Required Clinical Documentation

    Submit clinical notes from the treating provider that reference the applicable policy criteria and include all pertinent procedure codes. The record should be sufficiently specific for Health New England to evaluate the requested service.

    • Reference the relevant PNS, PNFS, or PENFS criteria in the treating-provider notes.
    • Include pertinent CPT codes, including the requested procedure and any related implantation, revision, removal, or generator services.
    Documentation Required

    Implantation Benefit Documentation

    Before permanent implantation, document that percutaneous stimulation effectively controlled the member’s pain and that implantation of electrodes is warranted. The physician must determine and record whether the member is likely to derive significant therapeutic benefit from continued use of an implanted nerve stimulator during a trial period of at least 1 month.

    • For a permanent implantable stimulator, document a successful stimulation trial producing at least a 50% reduction in pain intensity.
    • A trial is not required for a temporary stimulator such as Sprint; the remaining applicable criteria must still be documented.
    Documentation Required

    Clinical Eligibility Documentation

    Document the clinical eligibility elements for PNS or PNFS, including patient education and discussion of risks and benefits, absence of active substance-abuse issues, formal psychological screening showing no psychological contraindication, and objective evidence of pathology such as nerve-conduction testing or electromyography.

    • Record the education provided and the patient’s discussion of expected benefits, risks, and alternatives.
    • Include a substance-abuse assessment documenting no active substance-abuse issue.
    • Include a formal evaluation by a mental-health professional documenting no psychological contraindication to treatment.
    • Include objective diagnostic evidence supporting the pathology and the requested stimulation.
    Prior Authorization

    Submit Clinical Evidence

    The treating physician or primary care provider must submit clinical evidence showing that the patient meets the criteria for the requested treatment, testing, or surgical procedure. Without the required evidence and information, Health New England cannot properly review the prior-authorization request.

    • Submit the complete clinical record with the PA request rather than relying on the procedure code alone.
    • Coverage remains subject to the member’s benefit plan, applicable law, and any additional coverage determination guidelines.
    Denial Risk

    Excluded or Non-FDA-Approved Indications

    PNS or PNFS is considered investigational for post-herpetic neuralgia, fibromyalgia, phantom limb pain, diffuse polyneuropathy, angina pectoris, and other non-FDA-approved indications.

    • Clearly identify the diagnosis and the FDA-approved indication supporting the requested device or procedure.
    • Do not request coverage under the medically necessary PNS/PNFS criteria when the indication is excluded or not FDA approved.
    Denial Risk

    Criteria Not Satisfied

    PNS or PNFS requests that do not satisfy the applicable medical-necessity criteria are considered not medically necessary. Incomplete documentation of any required criterion can prevent approval.

    • Confirm that diagnosis, duration, treatment failure, education, substance-abuse assessment, psychological screening, objective pathology, and safety requirements are addressed as applicable.
    • For permanent implantation, also document the required successful stimulation trial and expected therapeutic benefit.
    Denial Risk

    Needle-Based Peripheral Stimulation

    Percutaneous electrical stimulation of a peripheral nerve using needles or needle electrodes is not covered under the policy and is not converted to a covered service by reporting an unlisted code.

    • Needle- or needle-electrode-based peripheral nerve stimulation is excluded.
    • CPT 64999 is experimental/investigational when used to describe this needle-based stimulation.
    Denial Risk

    Additional Lead

    An additional, second or subsequent lead of a peripheral nerve stimulator is considered experimental and investigational. Document the requested lead count and clinical rationale, but do not represent an additional lead as a covered standard lead.

    • The experimental/investigational designation applies to the second or any subsequent peripheral nerve stimulator lead.
    Denial Risk

    Nonqualifying PENFS Indication

    PENFS outside the specified qualifying gastrointestinal indications and criteria is considered experimental and investigational. The request must establish that the member meets the policy’s age, diagnosis, disease-exclusion, duration, and treatment-failure requirements.

    • Qualifying patients are children or adolescents ages 11–21 with a Rome IV-defined functional gastrointestinal disorder, including functional abdominal pain, functional abdominal pain syndrome, irritable bowel syndrome, functional dyspepsia, or abdominal migraine.
    • Document that organic gastrointestinal disease has been ruled out and that the problem has been present for at least 9 months.
    • PENFS for any other indication is experimental and investigational.
    Denial Risk

    Contraindications

    Screen for and document all stated contraindications before requesting PNS, PNFS, or implantation. The policy identifies BMI greater than 40, prior lumbar surgery, an implanted electronic device, pregnancy, and surgical risks such as infection as contraindication concerns.

    • BMI > 40
    • Prior lumbar surgery
    • Implanted electronic device
    • Pregnancy
    • Infection or other medical or surgical risk that contraindicates treatment
    Denial Risk

    Insufficient Clinical Documentation

    Requests may be denied or cannot be properly reviewed when clinical documentation is insufficient to support the requested treatment, testing, or eligibility criteria. Submit the treating-provider notes, pertinent codes, objective testing, treatment history, and documentation for every applicable criterion with the prior-authorization request.

    • Missing evidence of medical necessity, prior treatment failure, or objective pathology creates denial risk.
    • Missing documentation of patient education, risks and benefits, substance-abuse assessment, psychological evaluation, contraindication screening, or implantation benefit may prevent approval.
    • Health New England’s clinical criteria review does not by itself guarantee benefit coverage or payment; the member’s benefit plan governs when it differs from the policy.
    Distinction from PNSPNFS/PSFS targets a field of pain rather than a specific peripheral nerve
    Percutaneous electrical nerve field stimulation (PENFS)
    SystemIB-STIM is a percutaneous electrical nerve field stimulation system
    Nerve targetsThe system is applied to branches of cranial nerves V, VII, IX, and X and the occipital nerves
    UseIt is used with other therapies to aid reduction of functional abdominal pain associated with irritable bowel syndrome

    Examples include physical therapy, braces, local injections, analgesics such as gabapentin or pregabalin, and acupuncture.

    Failure of All Three Medication Categories Plus Diet Modification

    Before PENFS, qualifying gastrointestinal symptoms and all required medication and diet trials must be documented.

    PENFS conservative-treatment requirements

    • Qualifying gastrointestinal symptoms have been present for at least 9 months.≥9 months
    • Failure of all three medication categories plus diet modification

      • The patient has tried and failed acid-suppression medications, including H2 blockers or proton-pump inhibitors.
      • The patient has tried and failed antispasmodic or motility medications, including hyoscyamine, dicyclomine, erythromycin, linaclotide, or prucalopride.
      • The patient has tried and failed neuromodulators, including amitriptyline, nortriptyline, gabapentin, Periactin, or aprepitant.
      • The patient has completed diet modification.